Compare · NVO vs TAOX
NVO vs TAOX
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tao Synergies Inc. (TAOX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TAOX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $208.51B, about 7624.6x TAOX ($27.3M).
- NVO has hit the wire 4 times in the past 4 weeks while TAOX has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for TAOX).
- Company
- Novo Nordisk A/S
- Tao Synergies Inc.
- Price
- $47.09+0.02%
- $3.66+11.25%
- Market cap
- $208.51B
- $27.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TAOX
- TAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as Advisor
- TAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AI
- Amendment: SEC Form 10-K/A filed by Tao Synergies Inc.
- SEC Form 4 filed by Executive Chairman Silverman Joshua
- SEC Form 4 filed by Director Bernstein Bruce
- SEC Form 4 filed by Director Singer William S.
- SEC Form 4 filed by Chief Financial Officer Weinstein Robert
- SEC Form 4 filed by Director Ephron Robert
- SEC Form 10-Q filed by Tao Synergies Inc.
- SEC Form 4 filed by Singer William S.